Physician profile
Diane E Bite
NPI 1275847436
$7,177.30
in general payments reported to CMS, 2019-2025
30 companies · $2,049 in 2025
The $2,049 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $945 · 2022: $699 · 2023: $1,879 · 2024: $1,604 · 2025: $2,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,514 · Education: $18.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,514.13 |
| Education | $18.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,295.92 | 2021-2025 | Farxiga, Andexxa, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $971.71 | 2021-2025 | Jardiance, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $670.81 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $625.26 | 2022-2025 | Lifevest |
| Amgen INC. | $427.69 | 2021-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $425.17 | 2021-2025 | |
| Pfizer INC. | $355.52 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $336.88 | 2021-2025 | |
| United Therapeutics Corporation | $258.11 | 2021-2025 | Tyvaso, Orenitram, Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $255.05 | 2021-2025 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $249.43 | 2021-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $223.77 | 2021-2024 | Xarelto |
| Abiomed | $218.12 | 2024-2025 | Impella |
| Abbott Laboratories | $127.97 | 2021-2025 | Merlin@Home, Aveir, Thoratec Heartmate 3 Lvas Implant Kit |
| Biotronik INC. | $83.95 | 2022-2025 | Biomonitor |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $82.98 | 2024 | Onpattro |
| Dexcom, INC. | $75.01 | 2024-2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $73.29 | 2024 | Yupelri |
| Viatris Specialty LLC | $70.58 | 2025 | Yupelri |
| Heartflow, INC. | $59.97 | 2023-2025 | Ffrct |
| Lilly USA, LLC | $56.52 | 2025 | Zepbound, Mounjaro |
| Esperion Therapeutics, INC. | $51.97 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $36.48 | 2023 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $26.25 | 2025 | |
| Impel Pharmaceuticals INC. | $24.73 | 2022 | |
| Amarin Pharma, INC. | $21.21 | 2021 | |
| Scpharmaceuticals INC. | $19.70 | 2024 | |
| Novo Nordisk INC | $19.41 | 2025 | |
| Boston Scientific Corporation | $18.34 | 2024 | Varithena Administration Pack |
| Biohaven Pharmaceuticals, INC. | $15.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Bite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.